Abstract:Farnesoid X receptor (FXR) is a promising target for drug discovery against nonalcoholic fatty liver disease (NAFLD). However, no FXR agonist has been approved for NAFLD so far. The R & D of FXR agonists are somewhat hindered by the lack of effective and safe chemotypes. To this end, we developed a multi-stage computational workflow to screen the Specs and ChemDiv chemical library for FXR agonists, which consisted of machine learning (ML)-based classifiers, shape-based and electrostatic-based models, a FRED-based molecular docking protocol, an ADMET prediction protocol and substructure search. As a result, we identified a novel chemotype that has never been reported before, with compound XJ02862 (ChemDiv ID: Y020-6413) as the representative. By designing an asymmetric synthesis strategy, we were able to prepare four isomers of compound XJ02862. Interestingly, one of the isomers, 2-((S)-1-((2S,4R)-2-methyl-4-(phenylamino)-3,4-dihydroquinolin-1(2H)-yl)-1-oxopropan-2-yl)hexahydro-1H-isoindole-1,3(2H)-dione (XJ02862-S2), showed potent FXR agonistic activity in HEK293T cells. The molecular docking, molecular dynamics simulations and site-directed mutagenesis suggested the hydrogen bond between compound XJ02862-S2 and HIS294 of FXR is essential for ligand binding. We further demonstrated that compound XJ02862-S2 had no agonistic effect on TGR5. Further biological experiments have shown that compound XJ02862-S2 could ameliorate hypercholesterolemia, hepatic steatosis, hyperglycemia, insulin resistance (IR) in high-fat-diet induced obese (DIO) mice. In term of molecular mechanism, compound XJ02862-S2 regulates the expression of FXR downstream genes involved in lipogenesis, cholesterol transport and bile acid biosynthesis and transport. Taken together, we have discovered a novel chemotype as potent FXR agonists for NAFLD by computational modeling, chemical synthesis and biological evaluation.

Discovery of novel FFA4 (GPR120) receptor agonists with β-arrestin2-biased characteristics

Machine learning- and structure-based discovery of a novel chemotype as FXR agonists for potential treatment of nonalcoholic fatty liver disease

Label-free Cell Phenotypic Study of FFA4 and FFA1 and Discovery of Novel Agonists of FFA4 from Natural Products.

Design, synthesis and biological evaluations of novel farnesoid X receptor (FXR) agonists

Distinct binding hotspots for natural and synthetic agonists of FFA4 from in silico approaches

FFA4 Receptor (GPR120): A Hot Target for the Development of Anti-Diabetic Therapies.

Synthesis and evaluation of 3-(4-(phenoxymethyl)phenyl)propanoic acid and N-phenylbenzenesulfonamide derivatives as FFA4 agonists.

Synthesis, Activity, and Docking Study of Novel Phenylthiazole-Carboxamido Acid Derivatives as FFA2 Agonists

β-Arrestin Recruitment and Biased Agonism at Free Fatty Acid Receptor 1

Identification and functional characterization of allosteric agonists for the G protein-coupled receptor FFA2

Discovery of Novel Free Fatty Acid Receptor 1 Agonists Bearing Triazole Core Via Click Chemistry

Identification and target-pathway deconvolution of FFA4 agonists with anti-diabetic activity from Arnebia euchroma (Royle) Johnst

Biological characteristics and agonists of GPR120 (FFAR4) receptor: the present status of research

Design, Synthesis and Structure-Activity Relationship Studies of Novel Free Fatty Acid Receptor 1 Agonists Bearing Amide Linker.

Computational Insights into Molecular Activation and Positive Cooperative Mechanisms of FFAR1 Modulators.

Design, Synthesis and Biological Activity of Phenoxyacetic Acid Derivatives As Novel Free Fatty Acid Receptor 1 Agonists.

Structure-based design of free fatty acid receptor 1 agonists bearing non-biphenyl scaffold

Discovery of Β-Arrestin-biased Β2-Adrenoceptor Agonists from 2-Amino-2-phenylethanol Derivatives

A Selectivity Study of FFAR4/FFAR1 Agonists by Molecular Modeling

Identification and Pharmacological Characterization of Multiple Allosteric Binding Sites on the Free Fatty Acid 1 Receptor

Synthesis and Biological Evaluation of Phenoxyacetic Acid Derivatives As Novel Free Fatty Acid Receptor 1 Agonists.